Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. UBS analyst ...

The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the ...

ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, ...

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a price target of $16.00. The company’ ...

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV ...

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN). Such investors are advised to ...

John Houston, Ph.D., CEO of Arvinas, expressed optimism about the review process after presenting the findings at the American Society of Clinical Oncology’s annual meeting. Vepdegestrant has been ...

NEW HAVEN, Conn. - Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotech company with a market capitalization of $505 million and impressive revenue growth of nearly 500% over the last twelve months, ...

(Reuters) -An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.